Patents by Inventor Girij Pal Singh

Girij Pal Singh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190256498
    Abstract: The present invention provides novel crystalline form L1 of daclatasvir dihydrochloride wherein the diffraction peaks at 5.35, 6.04, 6.76, 8.65, 9.21, 10.35, 10.32, 10.75, 11.04, 11.66, 12.95, 13.56, 16.06, 18.11, 20.58, 22.18, 23.27±0.2 degree two theta in an X-ray diffraction pattern. The present invention provides novel crystalline form L2 of daclatasvir dihydrochloride wherein the diffraction peaks at 8.27, 9.54, 11.06, 13.61, 15.34, 19.01, 22.26, 23.24, 24.73, 25.35±0.2 degree two theta in an X-ray diffraction pattern. The present invention further provides process for preparation of crystalline forms L1 and L2 of daclatasvir dihydrochloride.
    Type: Application
    Filed: July 7, 2017
    Publication date: August 22, 2019
    Inventors: Palash SANPHUI, Radhakrishna Bhikaji SHIVDAVKAR, Gurvinder Pal SINGH, Purna Chandra RAY, Girij Pal SINGH, Vikas Ashokrao SADAPHAL, Lalitkumar Dilipising RAJPUT, Hemraj Mahadeorao LANDE
  • Publication number: 20190248773
    Abstract: The present invention provides improved, commercially viable and consistently reproducible processes for the preparation of pure and stable crystalline Raltegravir potassium Form 3 and pharmaceutical composition thereof.
    Type: Application
    Filed: September 13, 2017
    Publication date: August 15, 2019
    Inventors: Purna Chandra Ray, Samir Shanteshwar Shabade, Surinder Kumar Arora, D. Rajput Lalitkumar, B. Shivdavkar Radhakrishna, G. Varade Shantanu, D. Ausekar Govind, Girij Pal Singh, Shreyas Pandurang Deshmukh, Gaurav Amrut Patil
  • Patent number: 10377712
    Abstract: The present invention provides an improved process for preparation of an intermediate of apremilast. The present invention also provides an improved process for preparation of apremilast. This invention also provides novel polymorphs of apremilast. The present invention also provides pharmaceutical compositions of novel polymorphs of apremilast. This invention also provides a process for preparation of novel polymorphs of apremilast, which are cost-effective, robust, and viable at plant scale.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: August 13, 2019
    Assignee: LUPIN LIMITED
    Inventors: Palash Sanphui, Ananda Pundlik Sapdhare, Arunkumar Digambar Patil, Hemraj Mahadeorao Lande, Gurvinder Pal Singh, Puma Chandra Ray, Nandu Baban Bhise, Girij Pal Singh, Mithun Dasharath Surwase, Shantanu Gokuldas Varade, Govind Dnyanoba Ausekar, Radhakrishna Bhikaji Shivdavkar
  • Publication number: 20190135803
    Abstract: The present invention provides process for preparation of dihydroxy benzoquinoline compound (III) comprising reacting dihydroxy isoquinoline compound (IV) or a salt thereof with (2-acetyl-4-methyl-pentyl)-trimethyl-ammonium iodide (V) and further converting it to tetrabenazine (I) and deutetrabenazine (II).
    Type: Application
    Filed: April 12, 2017
    Publication date: May 9, 2019
    Applicant: Lupin Limited
    Inventors: Tushar Nandkumar DESPANDE, Dnyaneshwar Tukaram SINGARE, Yogesh Dadaji PAWAR, Yuvraj Atmaram CHAVAN, Purna Chandra RAY, Girij Pal SINGH
  • Patent number: 10259790
    Abstract: The present invention is directed to polymorphic forms of Pitavastatin sodium and processes for preparation of the same.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: April 16, 2019
    Assignee: LUPIN LIMITED
    Inventors: Narendra Dattatray Mane, Sagar Purushottam Nehate, Himanshu Madhav Godbole, Girij Pal Singh
  • Patent number: 10251850
    Abstract: The present invention provides process for preparation of cysteamine bitartrate comprising reacting cysteamine or its salt with tartaric acid. The present invention further provides crystalline form L1 of cysteamine bitartrate having characteristic diffraction peaks at 10.36, 14.54, 17.23, 18.03, 19.24, 20.76, 21.20, 22.02, 23.37, 23.64, 27.71, 28.28, 29.26, 31.33, 32.84, 33.83, 35.51, 36.74±0.2 degree two theta in an X-ray diffraction pattern and process for preparation thereof. The present invention provides crystalline form L2 of cysteamine bitartrate having characteristic diffraction peaks at 7.4, 10.3, 11.0, 11.4, 14.4, 14.9, 18.6, 19.4, 20.1, 20.8, 21.9, 22.3, 22.5, 23.5±0.2 degree two theta in an X-ray diffraction pattern and process for preparation thereof.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: April 9, 2019
    Assignee: LUPIN LIMITED
    Inventors: Pankaj Ramchandra Chaudhari, Sukhdeo Sampat Gunjal, Raju Muktaji Walunj, Anurag Trivedi, Rajinder Singh Siyan, Nandu Baban Bhise, Girij Pal Singh
  • Patent number: 10227317
    Abstract: Disclosed herein a process for the isolation of intermediate of Vortioxetine in a solid state form and an improved, commercially viable and industrially advantageous process for the preparation of vortioxetine or a pharmaceutically acceptable salt thereof, in high yield and purity.
    Type: Grant
    Filed: February 24, 2016
    Date of Patent: March 12, 2019
    Assignee: LUPIN LIMITED
    Inventors: Girij Pal Singh, Dhananjai Srivastava, Paramvir Bhadwal, Inamus Saqlain Ansari, Nilesh Shashikant Bhawsar
  • Publication number: 20190062332
    Abstract: The present invention relates to process for preparation of ledipasvir of formula 1 and its novel intermediates. The process involves reaction of compound of formula 2 with compound of formula 3 to yield a compound of formula 4, deprotection of compound of formula 4 to yield compound of formula 5 and conversion of compound of formula 5 to Ledipasvir wherein PG is an amine protecting group provided that amino protecting group is not carbomethyloxy (—COOCH3) group; X and Y are leaving groups.
    Type: Application
    Filed: January 28, 2017
    Publication date: February 28, 2019
    Inventors: Swapnil Sudhakar Deshmukh, Manoj Kunjabihari Agrawal, Adinath Murlidhar Jain, Himanshu Madhav Godbole, Girij Pal Singh
  • Publication number: 20190040066
    Abstract: The present invention relates to processes for the preparation of Phosphatidylinositol 3-Kinase Inhibitor (PI3K) compound of formula-1 via novel intermediates (I).
    Type: Application
    Filed: February 3, 2017
    Publication date: February 7, 2019
    Inventors: Sanket Pandurang Jadhav, Dipak Vasant Patil, Deepak Puna Mahajan, Sagar Purushottam Nehate, Himanshu Madhav Godbole, Girij Pal Singh
  • Publication number: 20180273481
    Abstract: The present invention is directed to polymorphic forms of Pitavastatin sodium and processes for preparation of the same.
    Type: Application
    Filed: April 6, 2018
    Publication date: September 27, 2018
    Applicant: LUPIN LIMITED
    Inventors: Narendra Dattatray MANE, Sagar Purushottam NEHATE, Himanshu Madhav GODBOLE, Girij Pal SINGH
  • Publication number: 20180230097
    Abstract: The present invention provides an improved process for preparation of an intermediate of apremilast. The present invention also provides an improved process for preparation of apremilast. This invention also provides novel polymorphs of apremilast. The present invention also provides pharmaceutical compositions of novel polymorphs of apremilast. This invention also provides a process for preparation of novel polymorphs of apremilast, which are cost-effective, robust, and viable at plant scale.
    Type: Application
    Filed: May 26, 2016
    Publication date: August 16, 2018
    Applicant: LUPIN LIMITED
    Inventors: Palash SANPHUI, Ananda Pundlik SAPDHARE, Arunkumar Digambar PATIL, Hemraj Mahadeorao LANDE, Gurvinder Pal SINGH, Purna Chandra RAY, Nandu Bahan BHISE, Girij Pal SINGH, Mithun Dasharath SURWASE, Shantanu Gokuldas VARADE, Govind Dnyanoba AUSEKAR, Radhakrishna Bhikaji SHIVDAVKAR
  • Publication number: 20180222836
    Abstract: A one-pot process is disclosed for the preparation of pharmaceutical grade ferric citrate that includes preparing a ferric hydroxide slurry followed by treatment with a citrate ion source to yield pharmaceutical grade ferric citrate.
    Type: Application
    Filed: August 4, 2016
    Publication date: August 9, 2018
    Inventors: Anurag Anil Smart, Yogesh Subhash Aher, Sunilkumar Vinubhai Gohel, Rajinder Singh Siyan, Nandu Baban Bhise, Girij Pal Singh
  • Publication number: 20180193292
    Abstract: The present invention provides process for preparation of cysteamine bitartrate comprising reacting cysteamine or its salt with tartaric acid. The present invention further provides crystalline form L1 of cysteamine bitartrate having characteristic diffraction peaks at 10.36, 14.54, 17.23, 18.03, 19.24, 20.76, 21.20, 22.02, 23.37, 23.64, 27.71, 28.28, 29.26, 31.33, 32.84, 33.83, 35.51, 36.74±0.2 degree two theta in an X-ray diffraction pattern and process for preparation thereof. The present invention provides crystalline form L2 of cysteamine bitartrate having characteristic diffraction peaks at 7.4, 10.3, 11.0, 11.4, 14.4, 14.9, 18.6, 19.4, 20.1, 20.8, 21.9, 22.3, 22.5, 23.5±0.2 degree two theta in an X-ray diffraction pattern and process for preparation thereof.
    Type: Application
    Filed: January 11, 2018
    Publication date: July 12, 2018
    Inventors: Pankaj Ramchandra CHAUDHARI, Sukhdeo Sampat GUNJAL, Raju Muktaji WALUNJ, Anurag TRIVEDI, Rajinder Singh SIYAN, Nandu Baban BHISE, Girij Pal SINGH
  • Publication number: 20180155270
    Abstract: The present invention provides one pot process for preparation of highly pure unsaturated cinacalcet hydrochloride (II) comprising: i) converting 3-(trifluromethyl) cinnamic acid (III) into 3-(3-(trifluoromethyl)phenyl)prop-2-en-1-ol (IV), ii) converting 3-(3-(trifluoromethyl)phenyl)prop-2-en-1-ol (IV) to compound (V), wherein R is Cl, Br, I, tosylate and mesylate, Formula (V) iii) reacting compound (V) with (R)-1-(1-Naphthyl) ethylamine (VI) in presence of base followed by treatment with hydrochloric acid. The present invention further provides conversion of unsaturated cinacalcet hydrochloride (II) to cinacalcet hydrochloride (I).
    Type: Application
    Filed: May 27, 2016
    Publication date: June 7, 2018
    Inventors: Vishal Gautam Gaikwad, Sadanand Nilkanth Patil, Rajinder Singh Siyan, Nandu Baban Bhise, Girij Pal Singh
  • Patent number: 9981927
    Abstract: The present invention is directed to process for preparation of ?-form crystal of Mirabegron, (R)-2-(2-aminothiazol-4-yl)-N-(4-(2-((2-hydroxy-2-phenylethyl) amino) ethyl) phenyl) acetamide of formula (1).
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: May 29, 2018
    Assignee: LUPIN LIMITED
    Inventors: Girij Pal Singh, Dhananjai Shrivastava, Paramvir Bhadwal, Malhari Deoram Bhor, Suryabhan Prabhakar Dange, Sonaraj Bholenath Jangam
  • Patent number: 9969691
    Abstract: The present invention is directed to polymorphic forms of Pitavastatin sodium and processes for preparation of the same.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: May 15, 2018
    Assignee: LUPIN LIMITED
    Inventors: Narendra Dattatray Mane, Sagar Purushottam Nehate, Himanshu Madhav Godbole, Girij Pal Singh
  • Publication number: 20180118714
    Abstract: The present invention provides an improved process for the preparation of Efinaconazole in higher yield by the ring-opening addition reaction of epoxytriazole with 4-methylenepiperidine or its acid addition salt under mild conditions without using a large excess of 4-methylenepiperidine in the presence of an alkali or an alkaline earth metal halide.
    Type: Application
    Filed: May 10, 2016
    Publication date: May 3, 2018
    Inventors: Sachin Arun SASANE, Devendrakumar Paramsukh VARMA, Rajesh Harishankar VYAS, Nandu Baban BHISE, Girij Pal SINGH, Krishnat Hanmant KUMBHAR
  • Publication number: 20180099991
    Abstract: The invention relates to salts of Obeticholic Acid, their amorphous and crystalline polymorphic form and processes for preparation thereof.
    Type: Application
    Filed: October 9, 2017
    Publication date: April 12, 2018
    Inventors: Palash Sanphui, Radhakrishna Bhikaji Shivdavkar, Rajesh Vyas, Nandu Baban Bhise, Girij Pal Singh
  • Patent number: 9932295
    Abstract: The present invention relates to a process for the preparation of Levothyroxine and salts thereof. The process described in the present invention provides increase in the yields and purity comprising the use of sodium iodide and sodium hypochlorite as iodinating agent.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: April 3, 2018
    Assignee: LUPIN LIMITED
    Inventors: Swapnil Sudhakar Deshmukh, Adinath Murlidhar Jain, Himanshu Madhav Godbole, Girij Pal Singh, Dinesh Dnyaneshwar Dixit
  • Publication number: 20180030008
    Abstract: Disclosed herein a process for the isolation of intermediate of Vortioxetine in a solid state form and an improved, commercially viable and industrially advantageous process for the preparation of vortioxetine or a pharmaceutically acceptable salt thereof, in high yield and purity.
    Type: Application
    Filed: February 24, 2016
    Publication date: February 1, 2018
    Inventors: Girij Pal Singh, Dhananjai Srivastava, Paramvir Bhadwal, Inamus Saqlain Ansari, Nilesh Shashikant Bhawsar